TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

TPEX:4157 Revenue

TaiGen Biopharmaceuticals Holdings had revenue of 8.23M TWD in the quarter ending June 30, 2026, a decrease of -23.14%. This brings the company's total for the last twelve months to 256.46M, up 530.40% year-over-year. In the year 2025, TaiGen Biopharmaceuticals Holdings had annual revenue of 259.47M with 72.24% growth. That makes TaiGen Biopharmaceuticals Holdings the 38,392nd largest company in the world by revenue and 2,002nd in Taiwan.

• Revenue (ttm): 256.46M
• Revenue Growth: +530.40%
• P/S Ratio: 21.68
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 5.56B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Research and Development of New Drugs 259.42M 100.0%
• The Others 58.00K 0.0%

By Geography

Chart

• Mainland China 190.07M 73.3%
• Taiwan 36.32M 14.0%
• India 31.56M 12.2%
• Vietnam 1.53M 0.6%

Fiscal year ended Dec 31, 2025 See the full TPEX:4157 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	259.47M	108.82M	72.24%
Dec 31, 2024	150.65M	27.52M	22.35%
Dec 31, 2023	123.13M	86.90M	239.87%
Dec 31, 2022	36.23M	-1.26B	-97.20%
Dec 31, 2021	1.29B	1.27B	5,426.95%

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error